RPID

LEXINGTON, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the grant on June 3, 2026, of 60,000 restricted stock units (“RSUs”) of the Company's Class A common stock (“Common Stock”) as a material inducement to employment for a new employee. Such equity award was made under the Company's Inducement Plan, as amended (the “Inducement Plan”) and was approved by a majority of the independent directors of the Board of Directors or a duly authorized committee thereof in accordance with Nasdaq Listing Rule 5635(c)(4). The equity award is subject to the terms and conditions of the Inducement Plan, and the terms and conditions of the applicable RSU award agreement covering the grant.

Bain Capital Life Sciences and Armistice Capital are investing approximately $9.8 million, with the potential of up to approximately $32 million in the event the warrants offered in this offering are exercised, to support the future success of the Company. Certain directors and officers of the Company are also investing in a concurrent registered offering Bain Capital Life Sciences and Armistice Capital are investing approximately $9.8 million, with the potential of up to approximately $32 million in the event the warrants offered in this offering are exercised, to support the future success of the Company. Certain directors and officers of the Company are also investing in a concurrent registered offering

Rapid Micro Biosystems NASDAQ: RPID reported first-quarter 2026 revenue growth and reaffirmed its full-year outlook, citing momentum in system placements, consumables and recurring revenue, while management said gross margin improvement remains a central priority for the year.

LEXINGTON, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the first quarter ended March 31, 2026.

LEXINGTON, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release first quarter 2026 financial results after the market close on Wednesday, May 13, 2026.

Rapid Micro Biosystems (RPID) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.